Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Atul Khullar

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Frontiers in Psychiatry|December 5, 2022
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potentialBrittany Chubbs, Jay Wang, Shaina Archer, et al.
Journal of Child and Adolescent Psychopharmacology|October 29, 2021
Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-UpMargaret Danielle Weiss, Craig Surman, Atul Khullar, et al.
Sleep Medicine|August 23, 2025
Effect of lemborexant on sleep parameters and architecture in adult and elderly participants with mild-to-severe obstructive sleep apneaAtul Khullar, Mark I Boulos, Michael S B Mak, et al.
Therapeutic Advances in Psychopharmacology|March 5, 2024
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depressionRaymond Yan, Tyler Marshall, Atul Khullar, et al.
CNS Drugs|February 15, 2022
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious PrescribingJennifer Swainson, Larry J Klassen, Stefan Brennan, et al.
Therapeutic Advances in Psychopharmacology|May 23, 2020
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkersDmitriy Matveychuk, Rejish K Thomas, Jennifer Swainson, et al.
Psychiatry Research|May 16, 2026
Ketamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesisIsis Lunsky, Gilmar Gutierrez, Xena Wang, et al.
Sleep Medicine: X|April 6, 2026
Effects of lemborexant on sleep quality and its association with morning alertness: Post hoc analysis of two phase 3 trialsMasahiro Suzuki, Takuya Yoshiike, Atul Khullar, et al.
The Primary Care Companion for CNS Disorders|November 12, 2016
Functional Recovery in Major Depressive Disorder: Focus on Early Optimized TreatmentJeffrey Habert, Martin A Katzman, Oloruntoba J Oluboka, et al.
Sleep Medicine|October 31, 2024
Delphi consensus recommendations for the management of chronic insomnia in CanadaCharles M Morin, Atul Khullar, Rebecca Robillard, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Psychiatry|December 5, 2022
A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potentialBrittany Chubbs, Jay Wang, Shaina Archer, et al.
Journal of Child and Adolescent Psychopharmacology|October 29, 2021
Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-UpMargaret Danielle Weiss, Craig Surman, Atul Khullar, et al.
Sleep Medicine|August 23, 2025
Effect of lemborexant on sleep parameters and architecture in adult and elderly participants with mild-to-severe obstructive sleep apneaAtul Khullar, Mark I Boulos, Michael S B Mak, et al.
Therapeutic Advances in Psychopharmacology|March 5, 2024
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depressionRaymond Yan, Tyler Marshall, Atul Khullar, et al.
CNS Drugs|February 15, 2022
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious PrescribingJennifer Swainson, Larry J Klassen, Stefan Brennan, et al.
Therapeutic Advances in Psychopharmacology|May 23, 2020
Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkersDmitriy Matveychuk, Rejish K Thomas, Jennifer Swainson, et al.
Psychiatry Research|May 16, 2026
Ketamine and esketamine for the prevention of postpartum depression: A systematic review and network meta-analysis, with an integrated evidence synthesisIsis Lunsky, Gilmar Gutierrez, Xena Wang, et al.
Sleep Medicine: X|April 6, 2026
Effects of lemborexant on sleep quality and its association with morning alertness: Post hoc analysis of two phase 3 trialsMasahiro Suzuki, Takuya Yoshiike, Atul Khullar, et al.
The Primary Care Companion for CNS Disorders|November 12, 2016
Functional Recovery in Major Depressive Disorder: Focus on Early Optimized TreatmentJeffrey Habert, Martin A Katzman, Oloruntoba J Oluboka, et al.
Sleep Medicine|October 31, 2024
Delphi consensus recommendations for the management of chronic insomnia in CanadaCharles M Morin, Atul Khullar, Rebecca Robillard, et al.
Pageof 3